Drug Shortage Report for NOVOLIN GE TORONTO
| Report ID | 280176 |
| Drug Identification Number | 02024233 |
| Brand name | NOVOLIN GE TORONTO |
| Common or Proper name | Novolin®ge Toronto |
| Company Name | NOVO NORDISK CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | INSULIN INJECTION HUMAN BIOSYNTHETIC |
| Strength(s) | 100UNIT |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | EA |
| Anatomical Therapeutical Chemical (ATC) code | A10AB |
| Anatomical Therapeutical Chemical (ATC) description | INSULINS AND ANALOGUES |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2026-03-09 |
| Actual start date | 2026-03-10 |
| Estimated end date | 2026-04-06 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-03-17 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 101-2476 ARGENTIA ROAD MISSISSAUGA, ONTARIO CANADA L5N 6M1 |
| Company contact information | 1 800 465 4334 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2026-03-17 | English | Compare |
| v2 | 2026-03-10 | French | Compare |
| v1 | 2026-03-10 | English | Compare |
Showing 1 to 3 of 3